SHR 3680

Drug Profile

SHR 3680

Alternative Names: SHR3680

Latest Information Update: 04 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Phase-I clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) in Australia (PO) (NCT02747342)
  • 20 Apr 2016 Jiangsu HengRui Medicine plans a phase I trial for Prostate cancer (Second-line therapy or greater, Metastatic disease, Castration-resistant) in Australia (PO) (NCT02747342)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top